Join the Rybelsus group to help and get support from people like you.
Rybelsus News (Page 5)
Glycemic Control Superior With Semaglutide 25 and 50 mg in Type 2 Diabetes
FRIDAY, Aug. 4, 2023 – Once-daily semaglutide 25 mg or 50 mg is superior to 14 mg for glycemic control among adults with type 2 diabetes, according to a study published online June 25 in The Lancet....
FDA Medwatch Alert: FDA Issues Warning About Compounded Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss
On May 30, 2023, the FDA posted information about medications containing semaglutide marketed for type 2 diabetes or weight loss. There are currently three FDA-approved semaglutide products which are...
Novo Nordisk Announces FDA Approval of Label Update for Rybelsus (semaglutide) Allowing Use as a First-Line Option for Adults with Type 2 Diabetes
People living with type 2 diabetes can now take Rybelsus®, the first and only oral glucagon-like peptide-1 (GLP-1) analog, along with diet and exercise, as initial therapy to help lower their A1C1,2 ...
FDA Approves Rybelsus (semaglutide), the First Oral GLP-1 Analog Treatment for Adults with Type 2 Diabetes
PLAINSBORO, N.J., Sept. 20, 2019 /PRNewswire/ – Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved Rybelsus (semaglutide) tablets 7 mg or 14 mg for adults...
Ask a question
To post your own question to this support group, sign in or create an account.